Terns Pharmaceuticals, Inc. (TERN) FY2024 10-K Annual Report
Terns Pharmaceuticals, Inc. (TERN) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Mar 20, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Terns Pharmaceuticals, Inc. FY2024 10-K Analysis
Business Overview
- • Core business: clinical-stage biopharmaceutical developing small-molecule therapies for serious diseases including oncology (CML) and obesity
- • New emphasis on TERN-701 allosteric BCR-ABL inhibitor for CML with positive Phase 1 data and FDA orphan drug designation in March 2024
- • Strategic focus shifted to best-in-class allosteric TKIs targeting BCR-ABL myristoyl pocket to overcome limitations of active-site TKIs and asciminib
- • Positive Phase 1 CARDINAL trial enrolled 19 patients, with 88% of baseline >1% BCR-ABL transcript patients showing treatment response, no dose-limiting toxicities
- • Noteworthy safety profile for TERN-701: no grade 3+ treatment-related adverse events or discontinuations, with once-daily dosing attractive for long-term CML therapy
Management Discussion & Analysis
- • No revenue from product sales in FY 2024 and 2023; potential milestone revenue from TERN-701 license in Greater China
- • Net loss $88.9M in 2024 vs $90.2M in 2023; operating expenses $101.9M vs $102.6M; R&D expenses rose 10% to $70.1M, G&A expenses decreased 19% to $31.8M
- • R&D spending highest on TERN-701 ($15.8M) and TERN-601 ($15.5M); steep decline in TERN-501 expenses from $17.8M to $0.9M
- • Cash, cash equivalents and marketable securities $358.2M at year-end; net cash used in operations $70.0M; raised $161.9M in Sept 2024 public offering
- • Management expects expenses and operating losses to remain significant; plans development milestones in CML and obesity; potential risks from capital needs and regulatory outcomes
Risk Factors
- • Regulatory risk: compliance with Section 404 of Sarbanes-Oxley Act may cause significant costs and penalties
- • Macroeconomic threat: global economic downturn may weaken demand and delay payments for potential approved drugs
- • Supply chain vulnerability: potential supply disruptions from manufacturers and vendors during pandemics or public health events
- • Market disruption risk: competitive clinical trial failures or delays, impacting development against industry peers
- • Financial risk: net operating loss carryforwards usage limited by IRS Section 382 ownership change rules
Terns Pharmaceuticals, Inc. FY2024 Key Financial MetricsXBRL
Net Income
-$89M
▲ +1.5% YoY
ROE
-25.7%
▲ +964bp YoY
Total Assets
$364M
▲ +35.5% YoY
EPS (Diluted)
$-1.12
▲ +11.8% YoY
Operating Cash Flow
-$70M
▼ -3.9% YoY
Source: XBRL data from Terns Pharmaceuticals, Inc. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Terns Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.